She has thirty years of experience in the fields of environmental health, risk assessment, molecular, cellular, and genetic toxicology, molecular epidemiology, biomonitoring, biomarkers, and DNA damage and repair. She is a visiting professor at the University of Oslo. From 1997 to 2017, she also taught at Comenius University in Bratislava. Until 2023, she was the head of the Health Effects Laboratory at NILU. Until 2006, she led the Department of Experimental Genetics at the Slovak Medical University in Bratislava (OECD GLP). In 2005-2006, she served as a national expert at the European Commission DG RTD Health in Brussels. In 2008-2009, she was a member of the advisory group for the 7th Framework Programme (environment, climate change).…

She is a graduate of the Faculty of Natural Sciences at Comenius University in Bratislava, specializing in genetics and molecular biology. Her professional career is closely tied to the Jessenius Faculty of Medicine at Comenius University in Martin, where she serves as the Director of the Martin Biomedical Center. Her research focuses on studying the genetic and molecular biological aspects of oncological diseases. She specializes in identifying new biomarkers related to an increased risk of malignancy, as well as biomarkers for early diagnosis and disease progression prediction. She is the author and co-author of 204 scientific publications (h-index 18). Throughout her career, she has been the principal investigator of four projects fun…

Dr. Sivakumar Murugadoss, a scientist at NILU Climate and Environmental Research Institute in Norway, specializes in in vitro toxicology and chemical safety. Holding a PhD in Biomedical Sciences from KU Leuven, he has investigated the health impacts of engineered nanomaterials through in vitro cell culture and animal models. His prior work at Sciensano and KU Leuven included contributions to European Horizon 2020 projects such as ALTERNATIVE and RISKGONE, where he developed Adverse Outcome Pathways (AOPs) and Integrated Approaches to Testing and Assessment (IATA) for cardiotoxicity and nanosafety. His current research focuses on advancing risk assessment and non-animal testing methods for regulatory use and the safety-by-design of chemic…